AU2016228806B2 - Method of purifying albumin-fusion proteins - Google Patents

Method of purifying albumin-fusion proteins Download PDF

Info

Publication number
AU2016228806B2
AU2016228806B2 AU2016228806A AU2016228806A AU2016228806B2 AU 2016228806 B2 AU2016228806 B2 AU 2016228806B2 AU 2016228806 A AU2016228806 A AU 2016228806A AU 2016228806 A AU2016228806 A AU 2016228806A AU 2016228806 B2 AU2016228806 B2 AU 2016228806B2
Authority
AU
Australia
Prior art keywords
sequence
comprises seq
loop comprises
seq
loop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016228806A
Other languages
English (en)
Other versions
AU2016228806A1 (en
Inventor
Mariko FONSECA
Alan Hunter
Yiming Li
Timothy PABST
Christopher Thompson
Liu TIE
Xiangyang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2016228806A1 publication Critical patent/AU2016228806A1/en
Application granted granted Critical
Publication of AU2016228806B2 publication Critical patent/AU2016228806B2/en
Priority to AU2021200423A priority Critical patent/AU2021200423B2/en
Priority to AU2023204271A priority patent/AU2023204271B2/en
Priority to AU2026201911A priority patent/AU2026201911A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016228806A 2015-03-12 2016-03-11 Method of purifying albumin-fusion proteins Active AU2016228806B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2021200423A AU2021200423B2 (en) 2015-03-12 2021-01-22 Method of purifying albumin-fusion proteins
AU2023204271A AU2023204271B2 (en) 2015-03-12 2023-07-03 Method of purifying albumin-fusion proteins
AU2026201911A AU2026201911A1 (en) 2015-03-12 2026-03-13 Method of purifying albumin-fusion proteins

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562132198P 2015-03-12 2015-03-12
US62/132,198 2015-03-12
PCT/US2016/022003 WO2016145307A1 (en) 2015-03-12 2016-03-11 Method of purifying albumin-fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021200423A Division AU2021200423B2 (en) 2015-03-12 2021-01-22 Method of purifying albumin-fusion proteins

Publications (2)

Publication Number Publication Date
AU2016228806A1 AU2016228806A1 (en) 2017-08-31
AU2016228806B2 true AU2016228806B2 (en) 2020-10-22

Family

ID=56878920

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2016228806A Active AU2016228806B2 (en) 2015-03-12 2016-03-11 Method of purifying albumin-fusion proteins
AU2021200423A Active AU2021200423B2 (en) 2015-03-12 2021-01-22 Method of purifying albumin-fusion proteins
AU2023204271A Active AU2023204271B2 (en) 2015-03-12 2023-07-03 Method of purifying albumin-fusion proteins
AU2026201911A Pending AU2026201911A1 (en) 2015-03-12 2026-03-13 Method of purifying albumin-fusion proteins

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2021200423A Active AU2021200423B2 (en) 2015-03-12 2021-01-22 Method of purifying albumin-fusion proteins
AU2023204271A Active AU2023204271B2 (en) 2015-03-12 2023-07-03 Method of purifying albumin-fusion proteins
AU2026201911A Pending AU2026201911A1 (en) 2015-03-12 2026-03-13 Method of purifying albumin-fusion proteins

Country Status (10)

Country Link
US (3) US10683340B2 (https=)
EP (2) EP3842451A1 (https=)
JP (3) JP6862348B2 (https=)
KR (2) KR20170124592A (https=)
CN (1) CN107428817B (https=)
AU (4) AU2016228806B2 (https=)
CA (2) CA2977675A1 (https=)
ES (1) ES2839211T3 (https=)
IL (1) IL253971B (https=)
WO (1) WO2016145307A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012323316B2 (en) 2011-10-11 2017-08-10 Viela Bio, Inc. CD40L-specific Tn3-derived scaffolds and methods of use thereof
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
CA3115341A1 (en) 2018-05-16 2019-11-21 Lib Therapeutics, Llc Compositions comprising pcsk9-binding molecules and methods of use
BR112021008797A2 (pt) * 2018-11-09 2021-08-31 Neopep Pharma Gmbh & Co. Kg Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
EP3711772A1 (en) * 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins
CN110295152A (zh) * 2019-07-29 2019-10-01 北京泓恩生物科技有限公司 一种重组产朊假丝酵母尿酸酶的纯化方法
US11180540B2 (en) * 2019-12-06 2021-11-23 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
CN115996940A (zh) * 2020-07-01 2023-04-21 免疫医疗有限责任公司 用于纯化生物治疗剂的洗涤剂和方法
CN112062833A (zh) * 2020-10-09 2020-12-11 国药集团武汉血液制品有限公司 一种从血浆组分ⅳ沉淀中提取人血白蛋白的方法
CN115677848A (zh) * 2022-10-24 2023-02-03 通化安睿特生物制药股份有限公司 一种制备高纯度高稳定性蛋白质的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120149873A1 (en) * 2009-05-07 2012-06-14 Novozymes Biopharma Dk A/S Method for purifying albumin

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007657A1 (en) 1999-07-27 2001-02-01 Phylos, Inc. Peptide acceptor ligation methods
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
ES2078518T3 (es) 1990-04-05 1995-12-16 Roberto Crea Mutagenesis por desplazamiento completo.
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE69935248T2 (de) 1998-12-02 2007-11-08 Adnexus Therapeutics, Inc., Waltham Dna-protein fusionen sowie anwendungen derselben
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US6951725B2 (en) 2001-06-21 2005-10-04 Compound Therapeutics, Inc. In vitro protein interaction detection systems
KR100524872B1 (ko) 2003-12-04 2005-11-01 씨제이 주식회사 인터페론 베타의 정제방법
JP4939410B2 (ja) 2004-07-06 2012-05-23 バイオレン，インク． 強化された特性を持つ変性ポリペプチドを発生させるためのルックスルー変異誘発
EP1976876A4 (en) 2005-12-22 2010-01-13 Conjuchem Biotechnologies Inc PROCESS FOR PRODUCING PREFORMED ALBUMIN CONJUGATES AND THERAPEUTIC AGENT
CN102014888A (zh) 2007-07-03 2011-04-13 达努塔·克鲁谢夫斯卡 α-酮戊二酸的新医药用途
US20090176654A1 (en) 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
EP2215246B1 (en) 2007-10-31 2015-01-07 MedImmune, LLC Protein scaffolds
BRPI0919881B1 (pt) 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
BRPI1008532B1 (pt) 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
CA2789337A1 (en) 2010-02-16 2011-08-25 Medimmune, Llc Hsa-related compositions and methods of use
CA2795325A1 (en) 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
CN103379915A (zh) 2011-02-15 2013-10-30 米迪缪尼有限公司 Hsa相关组合物及使用方法
AU2012323316B2 (en) * 2011-10-11 2017-08-10 Viela Bio, Inc. CD40L-specific Tn3-derived scaffolds and methods of use thereof
MX2015005363A (es) * 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120149873A1 (en) * 2009-05-07 2012-06-14 Novozymes Biopharma Dk A/S Method for purifying albumin

Also Published As

Publication number Publication date
WO2016145307A1 (en) 2016-09-15
IL253971A0 (en) 2017-10-31
IL253971B (en) 2021-10-31
AU2021200423A1 (en) 2021-02-25
JP2023103368A (ja) 2023-07-26
CN107428817B (zh) 2022-07-12
AU2023204271A1 (en) 2023-07-27
JP2018513124A (ja) 2018-05-24
CN107428817A (zh) 2017-12-01
KR20240093725A (ko) 2024-06-24
AU2026201911A1 (en) 2026-04-02
AU2016228806A1 (en) 2017-08-31
US20180105575A1 (en) 2018-04-19
JP7826243B2 (ja) 2026-03-09
CA2977675A1 (en) 2016-09-15
JP7320550B2 (ja) 2023-08-03
JP2021105025A (ja) 2021-07-26
US20230340074A1 (en) 2023-10-26
EP3268389A4 (en) 2018-08-08
AU2023204271B2 (en) 2026-04-02
BR112017019401A2 (pt) 2018-05-02
JP6862348B2 (ja) 2021-04-21
ES2839211T3 (es) 2021-07-05
CA3260163A1 (en) 2026-03-02
KR20170124592A (ko) 2017-11-10
EP3268389A1 (en) 2018-01-17
EP3268389B1 (en) 2020-09-30
US11548933B2 (en) 2023-01-10
EP3842451A1 (en) 2021-06-30
AU2021200423B2 (en) 2023-04-06
US20200407423A1 (en) 2020-12-31
US10683340B2 (en) 2020-06-16

Similar Documents

Publication Publication Date Title
AU2023204271B2 (en) Method of purifying albumin-fusion proteins
EP2771022B1 (en) Cd40l-specific tn3-derived scaffolds and methods of use thereof
CN110234355B (zh) 单体人IgG1 Fc和双特异性抗体
US9279014B2 (en) Methods for preparing an active TNFR-Fc fusion protein
CA3066893A1 (en) Cation exchange chromatography wash buffer
KR20210149779A (ko) Fc 영역 개변 항체의 정제 방법
KR20190099333A (ko) 유전자 조작 Fc 작제물에 관한 조성물 및 방법
JP2016519144A (ja) 最小限の単量体の分離を伴う組換えポリクローナル多量体の分離
JP2024539653A (ja) 生体液を精製するための組成物及び方法
KR20250148832A (ko) 알부민 융합 단백질의 정제방법
HK1245286B (en) Method of purifying albumin-fusion proteins
BR112017019401B1 (pt) Método de purificação de proteínas de fusão de albumina
BR122024023456A2 (pt) COMPOSIÇÃO COMPREENDENDO SUPORTES Tn3
RU2820588C2 (ru) Способы очистки гетеродимерных полиспецифических антител
RU2826189C2 (ru) Cd40l-специфичные каркасные структуры, происходящие из tn3, и способы их применения
HK40090436A (zh) Cd40l-特异性tn3-衍生的支架及其使用方法
HK40043765A (en) Cd40l-specific tn3-derived scaffolds and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)